Abstract

Daratumumab, pomalidomide, and dexamethasone (DPd) is an FDA-approved 3rd or later line of therapy for myeloma. However, as there are limited published data on the efficacy of 2nd-line DPd, we conducted a retrospective analysis (n = 33). Herein, we report our center’s data for 2nd-line DPd. Our patient population had a high amount of high risk cytogenetics (45.5%). The overall response rate (ORR) was 84.9% with a 1-year Progression Free Survival (PFS) of 37.7%. In standard risk myeloma (n = 18), the ORR was 88.9% and 1-year PFS was 61.1% (95% CI 42.3–88.3%). In high risk myeloma (45.5%, n = 15), the ORR was 80% with a 1-year PFS of 7.3% (95% CI 1.1–47.9%). This suggests that the efficacy of 2nd-line DPd in myeloma with high risk cytogenetics should be further investigated.

Original languageEnglish
Pages (from-to)3043-3046
Number of pages4
JournalLeukemia and Lymphoma
Volume62
Issue number12
DOIs
StatePublished - 2021

Keywords

  • Myeloma
  • antibody-based immunotherapy
  • chemotherapeutic approaches
  • cytogenetics
  • drug resistance
  • immunotherapy

Fingerprint

Dive into the research topics of 'A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma'. Together they form a unique fingerprint.

Cite this